PRECISION BIOSCIENCES INC Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings
PRECISION BIOSCIENCES INC (DTIL) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings of $630.00 thousand for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-27.
Discontinued › Income Statement › Other Income
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1 · last filed 2024-03-27
- PRECISION BIOSCIENCES INC fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, gain (loss) included in earnings for the quarter ending 2023-12-31 was $1.08M.
- PRECISION BIOSCIENCES INC fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, gain (loss) included in earnings for the quarter ending 2021-12-31 was $2.28M.
- PRECISION BIOSCIENCES INC fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, gain (loss) included in earnings for fiscal 2023 was $630.00K.
- PRECISION BIOSCIENCES INC fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, gain (loss) included in earnings for fiscal 2022 was -$515.00K, a 120.17% decline from fiscal 2021.
- PRECISION BIOSCIENCES INC fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, gain (loss) included in earnings for fiscal 2021 was $2.55M.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings 12 month |
|---|---|---|---|
| 2023-12-31 | $1.08M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-27 | $630.00K 10-K · filed 2024-03-27 | |
| 2023-09-30 | -$448.00K 10-Q · filed 2023-11-07 | ||
| 2022-12-31 | -$515.00K 10-K · filed 2023-03-09 | ||
| 2021-12-31 | $2.28M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | $2.55M 10-K · filed 2022-03-15 | |
| 2021-09-30 | $274.00K 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |